ScholarIQanswers from OpenAlex

Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease

PaperCitations, authors & open-access status

Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease have?

ScholarIQcitation count

Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease has 121 citations in the OpenAlex counts ScholarIQ stores.

When was Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease published?

ScholarIQyear

Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease has 2022 year in the ScholarIQ index.

What is the open-access status of Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease?

ScholarIQoa status

Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease has bronze oa status in the ScholarIQ index.

What is the DOI of Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease?

ScholarIQdoi

The DOI for Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease is on the source record.

What is the PMID of Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease?

ScholarIQpmid

The PMID for Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease is on the source record.

What is the OpenAlex record for Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease?

ScholarIQopenalex

The OpenAlex for Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial